Talarozole
Systematic (IUPAC) name
N-(2-Benzothioazolyl)-N-[4-[2-ethyl-1-(1,2,4-triazo-1-yl)butyl]phenyl]amine
Identifiers
CAS number	201410-53-9
ATC code	none
PubChem	?
Chemical data
Formula	C21H23N5S
Mol. mass	377.505 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	oral, topical

Talarozole (formerly R115866, planned trade name Rambazole) is an investigational drug for the treatment of acne, psoriasis and other keratinization disorders.

Talarozole inhibits the metabolism of retinoic acid by blocking the cytochrome P450 enzyme isoform CYP26, a retinoic acid hydroxylase. Because of this mechanism, it is called a retinoic acid metabolism blocking agent (RAMBA).^[1]

This section appears to have been copied and pasted from a source, possibly in violation of a copyright. Please edit this article to remove any non-free copyrighted content and attribute free content correctly. Follow the Guide to layout and the Manual of Style. Remove this template after editing. (March 2009)

Talarozole, being developed by Barrier Therapeutics Inc under license from Johnson & Johnson, is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid for the treatment of psoriasis and acne. Phase II clinical trials of an oral formulation of talarozole in patients with psoriasis and with acne, and a phase I clinical trial of a topical formulation have been completed. At the time of publication, Barrier Therapeutics had suspended the development of talarozole as part of a series of cost-cutting initiatives; the company had also been acquired by Stiefel Laboratories Inc. No formal announcement had been made regarding the further development of talarozole.^[2]

[edit] References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it. v • d • e